Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.60 |
| ▸ | SHBG | P04278 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6562809 | 0.82 | TAAR1 (0.75) | TAAR1SHBGNPC1MAPTRAB9A | |
| Hydrochloric Acid SCHEMBL6563360 | 0.79 | TAAR1 (0.71) | TAAR1SHBGNPC1MAPTRAB9A | |
| SCHEMBL578291 | 0.78 | NPC1 (0.44) | TAAR1NPC1MAPTRAB9A | |
| SCHEMBL18706249 | 0.77 | TAAR1 (0.35) | TAAR1 | |
| SCHEMBL27666552 | 0.76 | — | — | |
| SCHEMBL317457 | 0.76 | CNR1 (0.38) | TAAR1SHBGESR1ESR2 | |
| SCHEMBL1032610 | 0.76 | TAAR1 (0.33) | TAAR1SHBGESR1ESR2 | |
| SCHEMBL236446 | 0.76 | SHBG (0.56) | TAAR1SHBGMAPTESR1ESR2 | |
| SCHEMBL21684968 | 0.76 | TAAR1 (0.33) | TAAR1SHBGESR1ESR2 | |
| SCHEMBL16035570 | 0.76 | TAAR1 (0.33) | TAAR1SHBGESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-07 | — | — | US | claimed |
| EP-3371151-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | Agency For Science, Technology And Research (SG) | 2018-09-12 | — | — | EP | claimed |
| WO-2018151678-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-08-23 | — | — | WO | claimed |
| CN-108419435-A | Compound and epigenetics for treating cancer | 新加坡科技研究局 | 2018-08-17 | — | — | CN | claimed |
| CN-108348871-A | Highly branched, non-crosslinked aerogels, method for the production thereof and use thereof | 蓝移材料有限公司 | 2018-07-31 | — | — | CN | claimed |
| WO-2017061957-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-04-13 | — | — | WO | claimed |
| CN-100469817-C | Methods for the preparation of poly(etherimides)s | GEN ELECTRIC (US) | 2009-03-18 | — | — | CN | claimed |
| CN-1615331-A | Methods for the preparation of poly(etherimides)s | GEN ELECTRIC (US) | 2005-05-11 | — | — | CN | claimed |
| CN-109563103-A | modulators of beta-3 adrenergic receptors for the treatment or prevention of disorders related thereto | 艾尼纳制药公司 | 2019-04-02 | — | — | CN | disclosed |
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-07 | — | — | US | disclosed |
| CN-106165164-B | Method for manufacturing electrode | 宇部兴产株式会社 | 2019-01-22 | — | — | CN | disclosed |
| EP-3371151-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | Agency For Science, Technology And Research (SG) | 2018-09-12 | — | — | EP | disclosed |
| WO-2018151678-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-08-23 | — | — | WO | disclosed |
| CN-108419435-A | Compound and epigenetics for treating cancer | 新加坡科技研究局 | 2018-08-17 | — | — | CN | disclosed |
| CN-1845959-A | Flame retardant thermoplastic films and methods of making the same | GEN ELECTRIC (US) | 2006-10-11 | — | — | CN | disclosed |
| CN-1791641-A | Flame resistant thermoplastic composition, articles thereof and method of making articles | GEN ELECTRIC (US) | 2006-06-21 | — | — | CN | disclosed |
| US-20060019822-A1 | Palladium catalyst composition | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2006-01-26 | — | — | US | disclosed |
| CN-1681592-A | Palladium catalyst composition | WAKO PURE CHEMICAL INDUSTIES L (JP) | 2005-10-12 | — | — | CN | disclosed |
| EP-1537913-A1 | PALLADIUM CATALYST COMPOSITION | Wako Pure Chemical Industies, Ltd. (JP) | 2005-06-08 | — | — | EP | disclosed |
| CN-1615331-A | Methods for the preparation of poly(etherimides)s | GEN ELECTRIC (US) | 2005-05-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | SMYD3, SMYD2, EHMT1 | TAAR1 3566/4885SHBG 3654/4885NPC1 2706/4885 |
| US-20060019822-A1 | Palladium catalyst composition | ODC1, NUDC, ADH1C | TAAR1 2927/4885SHBG 4819/4885NPC1 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.